Research & Development
EU signs deal with GSK for supply of 220,000 treatments of its COVID-19 drug
28 July 2021 -

The European Union has signed a contract with British pharmaceutical company GlaxoSmithKline Plc (LON:GSK) for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, Reuters news agency reported on Wednesday.

According to the European commission, this drug, which is being developed together with US firm Vir Biotechnology (Nasdaq:VIR), can be used for the treatment of high-risk COVID-19 patients with mild symptoms, who do not require supplemental oxygen.

Currently, this drug is being assessed by the European Medicines Agency (EMA) under a rolling review.

This contract has been signed by 16 of the 27 EU states, which could buy the drug only after it is approved by EMA or by national drug regulators, Reuters added.



Related Headlines